A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AN OXYTOCIN-RECEPTOR ANTAGONIST(ANTOCIN) IN THE TREATMENT OF PRETERM LABOR. • 1054

Pediatric Research ◽

10.1203/00006450-199704001-01073 ◽

1997 ◽

Vol 41 ◽

pp. 178-178

Author(s):

Baha M. Sibai

Keyword(s):

Receptor Antagonist ◽

Preterm Labor ◽

Controlled Trial ◽

Oxytocin Receptor ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue

American Journal of Obstetrics and Gynecology ◽

10.1067/mob.2000.95834 ◽

2000 ◽

Vol 182 (5) ◽

pp. 1173-1183 ◽

Author(s):

Roberto Romero ◽

Baha M. Sibai ◽

Luis Sanchez-Ramos ◽

Guillermo J. Valenzuela ◽

Jean-Claude Veille ◽

...

Keyword(s):

Receptor Antagonist ◽

Preterm Labor ◽

Controlled Trial ◽

Oxytocin Receptor ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A double-blind placebo-controlled trial of an oxytocin-receptor antagonist (antocin) in the treatment of preterm labor

American Journal of Obstetrics and Gynecology ◽

10.1016/s0002-9378(97)80072-5 ◽

1997 ◽

Vol 176 (1) ◽

pp. S2 ◽

Author(s):

B.M. Sibai ◽

R. Romero ◽

L. Sanchez-Ramos ◽

G. Valenzuela ◽

J.C. Veille ◽

...

Keyword(s):

Receptor Antagonist ◽

Preterm Labor ◽

Controlled Trial ◽

Oxytocin Receptor ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A double-blind placebo-controlled trial of oxytocin receptor antagonist (Antocin) maintenance therapy in patients with preterm labor

American Journal of Obstetrics and Gynecology ◽

10.1016/s0002-9378(97)80139-1 ◽

1997 ◽

Vol 176 (1) ◽

pp. S30 ◽

Author(s):

L. Sanchez-Ramos ◽

G. Valenzuela ◽

R. Romero ◽

H. Silver ◽

W. Koltun ◽

...

Keyword(s):

Maintenance Therapy ◽

Receptor Antagonist ◽

Preterm Labor ◽

Controlled Trial ◽

Oxytocin Receptor ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF OXYTOCIN RECEPTOR ANTAGONIST(ANTOCIN) MAINTENANCE THERAPY IN PATIENTS WITH PRETERM LABOR. † 1031

Pediatric Research ◽

10.1203/00006450-199704001-01050 ◽

1997 ◽

Vol 41 ◽

pp. 174-174

Author(s):

Luis Sanchez-Ramos

Keyword(s):

Maintenance Therapy ◽

Receptor Antagonist ◽

Preterm Labor ◽

Controlled Trial ◽

Oxytocin Receptor ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

350: A multicenter, randomized, double-blind, placebo-controlled phase 2 trial of retosiban, a selective oxytocin receptor antagonist, for the management of preterm labor

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2012.10.515 ◽

2013 ◽

Vol 208 (1) ◽

pp. S155 ◽

Author(s):

Jerry Snidow ◽

Hugh Miller ◽

Guillermo Valenzuela ◽

Steve Thornton ◽

Brendt Stier ◽

...

Keyword(s):

Receptor Antagonist ◽

Preterm Labor ◽

Oxytocin Receptor ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia

European Journal of Pain ◽

10.1016/j.ejpain.2010.09.013 ◽

2011 ◽

Vol 15 (5) ◽

pp. 509-514 ◽

Author(s):

Pascale Vergne-Sallel ◽

Carine Dufauret-Lombardl ◽

Christine Bonnetl ◽

Anne Simonl ◽

Richard Trèvesl ◽

...

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2009.01.015 ◽

2009 ◽

Vol 200 (6) ◽

pp. 627.e1-627.e10 ◽

Author(s):

Steven Thornton ◽

Thomas M. Goodwin ◽

Gorm Greisen ◽

Morten Hedegaard ◽

Joan-Carles Arce

Keyword(s):

Gestational Age ◽

Preterm Labor ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Threatened Preterm Labor ◽

Oxytocin Antagonist

Download Full-text

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Annals of the Rheumatic Diseases ◽

10.1136/ard.2010.134254 ◽

2010 ◽

Vol 70 (5) ◽

pp. 747-754 ◽

Author(s):

P. Quartier ◽

F. Allantaz ◽

R. Cimaz ◽

P. Pillet ◽

C. Messiaen ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist ◽

Download Full-text

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Endocrine ◽

10.1007/s12020-018-1597-1 ◽

2018 ◽

Vol 62 (2) ◽

pp. 371-380 ◽

Author(s):

Barry Gumbiner ◽

Brooke Esteves ◽

Vanessa Dell ◽

Tenshang Joh ◽

Pamela D. Garzone ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Phase 1 ◽

Double Blind ◽

Glucagon Receptor ◽

Double Blind Placebo ◽

Glucagon Receptor Antagonist

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text